Omega-3 and omega-6 polyunsaturated fatty acids (PUFAs), such as α-linolenic and linoleic acids, are essential fatty acids in mammals, because they cannot be synthesized de novo. However, fat-1 transgenic mice can synthesize omega-3 PUFAs from omega-6 PUFAs without dietary supplementation of omega-3, leading to abundant omega-3 PUFA accumulation in various tissues. In this study, we used fat-1 transgenic mice to investigate the role of omega-3 PUFAs in response to inflammatory pain. A high omega-3 PUFA tissue content attenuated formalin-induced pain sensitivity, microglial activation, inducible nitric oxide synthase expression, and the phosphorylation of NR2B, a subunit of the N-methyl-d-aspartate (NMDA) receptor. Our findings suggest that elevated omega-3 PUFA levels inhibit NMDA receptor activity in the spinal dorsal horn and modulate inflammatory pain transmission by regulating signal transmission at the spinal dorsal horn, leading to the attenuation of chemically induced inflammatory pain.
Get full access to this article
View all access options for this article.
References
1.
InnisSM, GilleyJ, WerkerJ: Are human milk long-chain polyunsaturated fatty acids related to visual and neural development in breast-fed term infants?. J Pediatr, 2001; 139:532–538.
2.
CohenLA: Lipids in cancer: An introduction. Lipids, 1992; 27:791–792.
3.
MoriTA, BurkeV, PuddeyIB, et al.: Purified eicosapentaenoic and docosahexaenoic acids have differential effects on serum lipids and lipoproteins, LDL particle size, glucose, and insulin in mildly hyperlipidemic men. Am J Clin Nutr, 2000; 71:1085–1094.
4.
UauyR, DangourAD: Nutrition in brain development and aging: Role of essential fatty acids. Nutr Rev, 2006; 64:S24–S33; discussion S72–S91.
5.
SuKP, HuangSY, ChiuCC, ShenWW: Omega-3 fatty acids in major depressive disorder. A preliminary double-blind, placebo-controlled trial. Eur Neuropsychopharmacol, 2003; 13:267–271.
6.
RichardsonAJ: Omega-3 fatty acids in ADHD and related neurodevelopmental disorders. Int Rev Psychiatry, 2006; 18:155–172.
7.
KalmijnS: Fatty acid intake and the risk of dementia and cognitive decline: A review of clinical and epidemiological studies. J Nutr Health Aging, 2000; 4:202–207.
8.
RiedigerND, OthmanRA, SuhM, MoghadasianMH: A systemic review of the roles of n-3 fatty acids in health and disease. J Am Diet Assoc, 2009; 109:668–679.
9.
ArterburnLM, HallEB, OkenH: Distribution, interconversion, and dose response of n-3 fatty acids in humans. Am J Clin Nutr, 2006; 83:1467S–1476S.
10.
NobreME, CorreiaAO, Borges MdeB, et al.: Eicosapentaenoic acid and docosahexaenoic acid exert anti-inflammatory and antinociceptive effects in rodents at low doses. Nutr Res, 2013; 33:422–433.
11.
YatesCM, CalderPC, Ed RaingerG: Pharmacology and therapeutics of omega-3 polyunsaturated fatty acids in chronic inflammatory disease. Pharmacol Ther, 2014; 141:272–282.
12.
CalderPC: Omega-3 polyunsaturated fatty acids and inflammatory processes: Nutrition or pharmacology?. Br J Clin Pharmacol, 2013; 75:645–662.
KangJX: A transgenic mouse model for gene-nutrient interactions. J Nutrigenet Nutrigenomics, 2008; 1:172–177.
15.
TjolsenA, BergeOG, HunskaarS, RoslandJH, HoleK: The formalin test: An evaluation of the method. Pain, 1992; 51:5–17.
16.
AbbadieC, TaylorBK, PetersonMA, BasbaumAI: Differential contribution of the two phases of the formalin test to the pattern of c-fos expression in the rat spinal cord: Studies with remifentanil and lidocaine. Pain, 1997; 69:101–110.
17.
SmithHS: Activated microglia in nociception. Pain Physician, 2010; 13:295–304.
18.
SwettJE, WoolfCJ: The somatotopic organization of primary afferent terminals in the superficial laminae of the dorsal horn of the rat spinal cord. J Comp Neurol, 1985; 231:66–77.
19.
BoettgerMK, UceylerN, ZelenkaM, et al.: Differences in inflammatory pain in nNOS-, iNOS- and eNOS-deficient mice. Eur J Pain, 2007; 11:810–818.
20.
JiRR, GereauRW4th, MalcangioM, StrichartzGR: MAP kinase and pain. Brain Res Rev, 2009; 60:135–148.
21.
JiRR: Peripheral and central mechanisms of inflammatory pain, with emphasis on MAP kinases. Curr Drug Targets Inflamm Allergy, 2004; 3:299–303.
22.
VasquezC, SanchezM, HerreraJ, QuinteroG: Reduction of inflammatory pain in female rats after NR2B NMDA cortical antagonism. Psicothema, 2012; 24:296–301.
23.
LiuzziGM, LatronicoT, RossanoR, ViggianiS, FasanoA, RiccioP: Inhibitory effect of polyunsaturated fatty acids on MMP-9 release from microglial cells-implications for complementary multiple sclerosis treatment. Neurochem Res, 2007; 32:2184–2193.
24.
FuKY, LightAR, MaixnerW: Relationship between nociceptor activity, peripheral edema, spinal microglial activation and long-term hyperalgesia induced by formalin. Neuroscience, 2000; 101:1127–1135.
KoGD, NowackiNB, ArseneauL, EitelM, HumA: Omega-3 fatty acids for neuropathic pain: Case series. Clin J Pain, 2010; 26:168–172.
27.
WhiteFA, JungH, MillerRJ: Chemokines and the pathophysiology of neuropathic pain. Proc Natl Acad Sci USA, 2007; 104:20151–20158.
28.
De AlbaJ, ClaytonNM, CollinsSD, ColthupP, ChessellI, KnowlesRG: GW274150, a novel and highly selective inhibitor of the inducible isoform of nitric oxide synthase (iNOS), shows analgesic effects in rat models of inflammatory and neuropathic pain. Pain, 2006; 120:170–181.
29.
FerreiraSH: Inflammatory pain: The role of cytokines and its control by drugs which release nitric oxide. Ann Ist Super Sanita, 1993; 29:367–373.
30.
RennoWM: Prolonged noxious stimulation increases periaqueductal gray NMDA mRNA expression: A hybridization study using two different rat models for nociception. Ir J Med Sci, 1998; 167:181–192.
31.
WuLJ, ToyodaH, ZhaoMG, et al.: Upregulation of forebrain NMDA NR2B receptors contributes to behavioral sensitization after inflammation. J Neurosci, 2005; 25:11107–11116.
32.
ZhaoMG, KoSW, WuLJ, et al.: Enhanced presynaptic neurotransmitter release in the anterior cingulate cortex of mice with chronic pain. J Neurosci, 2006; 26:8923–8930.
33.
VaccarinoAL, ClemmonsHR, MaderGJJr, MagnussonJE: A role of periaqueductal grey NMDA receptors in mediating formalin-induced pain in the rat. Neurosci Lett, 1997; 236:117–119.
34.
LuY, ZhaoLX, CaoDL, GaoYJ: Spinal injection of docosahexaenoic acid attenuates carrageenan-induced inflammatory pain through inhibition of microglia-mediated neuroinflammation in the spinal cord. Neuroscience, 2013; 241:22–31.
35.
DaulhacL, MalletC, CourteixC, et al.: Diabetes-induced mechanical hyperalgesia involves spinal mitogen-activated protein kinase activation in neurons and microglia via N-methyl-D-aspartate-dependent mechanisms. Mol Pharmacol, 2006; 70:1246–1254.
36.
BogdanC, RollinghoffM, DiefenbachA: Reactive oxygen and reactive nitrogen intermediates in innate and specific immunity. Curr Opin Immunol, 2000; 12:64–76.
37.
ColemanJW: Nitric oxide in immunity and inflammation. Int Immunopharmacol, 2001; 1:1397–1406.
38.
GaoX, KimHK, ChungJM, ChungK: Reactive oxygen species (ROS) are involved in enhancement of NMDA-receptor phosphorylation in animal models of pain. Pain, 2007; 131:262–271.
